Martin Hutchings
MD, PhD
Associate Professor of Hematology
👥Biography 个人简介
Martin Hutchings at Rigshospitalet Copenhagen was a key investigator in the development of glofitamab, a bivalent CD20xCD3 bispecific requiring obinutuzumab pretreatment to manage CRS in DLBCL. His clinical trial work has helped define the role of bispecific antibodies as fixed-duration therapies for relapsed/refractory lymphoma. He has contributed to understanding the pharmacodynamic rationale for obinutuzumab pretreatment to reduce target antigen burden and CRS risk. His research integrates PET imaging, biomarker assessment, and clinical outcomes for lymphoma bispecifics.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Martin Hutchings 的研究动态
Follow Martin Hutchings's research updates
留下邮箱，当我们发布与 Martin Hutchings（Rigshospitalet Copenhagen University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment